Literature DB >> 1332594

In vitro activity of T-3761, a new fluoroquinolone.

T Muratani1, M Inoue, S Mitsuhashi.   

Abstract

The in vitro activity of T-3761, a new fluoroquinolone antimicrobial agent which has an oxazine ring structure with a cyclopropyl moiety at C-10, was compared with those of other agents against 2,854 clinical isolates. T-3761 had a broad spectrum of activity and had potent activity against gram-positive and -negative bacteria. The MICs of T-3761 against 90% of the methicillin-susceptible Staphylococcus aureus, methicillin-susceptible and -resistant Staphylococcus epidermidis, and Clostridium spp. tested were 0.39 to 6.25 micrograms/ml. Its activity was comparable to those of ciprofloxacin and ofloxacin and four- to eightfold greater than those of norfloxacin and fleroxacin, but its activity was two- to eightfold less than that of tosufloxacin. Some isolates of ciprofloxacin-resistant S. aureus (MIC of ciprofloxacin, greater than or equal to 3.13 micrograms/ml) were still susceptible to T-3761 (MIC of T-3761, less than or equal to 0.78 micrograms/ml). The MICs of T-3761 against 90% of the streptococci and enterococci tested were 3.13 to 100 micrograms/ml. Its activity was equal to or 2- or 4-fold greater than those of norfloxacin and fleroxacin, equal to or 2- or 4-fold less than those of ofloxacin and ciprofloxacin, and 4- to 16-fold less than that of tosufloxacin. The activity of T-3761 against gram-negative bacteria was usually fourfold greater than those of norfloxacin, ofloxacin, and fleroxacin. Many isolates which were resistant to nonfluoroquinolone agents, such as minocycline- or imipenem-resistant S. aureus, ceftazidime-resistant members of the family Enterobacteriaceae, gentamicin- or imipenem-resistant Pseudomonas aeruginosa, and ampicillin-resistant Haemophilus influenzae and Neisseria gonorrhoeae, were susceptible to T-3761. The MBCs of T-3761 were either equal to or twofold greater than the MICs. The number of viable cells decreased rapidly during incubation with T-3761 at one to four times the MIC. At a concentration of four times the MIC, the frequencies of appearance of spontaneous mutants resistant to T-3761 against S. aureus, Escherichia coli, Serratia marcescens, and P. aeruginosa were 2.2 x 10(-8) to less than or equal to 1.2 x 10(-9). The 50% inhibitory concentrations of T-3761 for DNA gyrases isolated from E. coli and P. aeruginosa were 0.88 and 1.9 micrograms/ml, respectively.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1332594      PMCID: PMC245492          DOI: 10.1128/AAC.36.10.2293

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  DNA gyrase: purification and catalytic properties of a fragment of gyrase B protein.

Authors:  M Gellert; L M Fisher; M H O'Dea
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

2.  Some properties of subunits of DNA gyrase from Pseudomonas aeruginosa PAO1 and its nalidixic acid-resistant mutant.

Authors:  Y Inoue; K Sato; T Fujii; K Hirai; M Inoue; S Iyobe; S Mitsuhashi
Journal:  J Bacteriol       Date:  1987-05       Impact factor: 3.490

3.  In vitro antibacterial activity of a new quinolone, NM394.

Authors:  M Ozaki; M Matsuda; Y Tomii; K Kimura; K Kazuno; M Kitano; M Kise; K Shibata; M Otsuki; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

4.  In vitro activity of AT-4140 against quinolone- and methicillin-resistant Staphylococcus aureus.

Authors:  T Kojima; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

5.  In vitro antibacterial activity of DR-3355, the S-(-)-isomer of ofloxacin.

Authors:  T Fujimoto; S Mitsuhashi
Journal:  Chemotherapy       Date:  1990       Impact factor: 2.544

6.  In vitro activity of AT-4140 against clinical bacterial isolates.

Authors:  T Kojima; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

7.  Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies.

Authors:  M W Hane; T H Wood
Journal:  J Bacteriol       Date:  1969-07       Impact factor: 3.490

8.  Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; T Itoh; J I Tomizawa
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

9.  Purification of Citrobacter freundii DNA gyrase and inhibition by quinolones.

Authors:  H Aoyama; K Sato; T Fujii; K Fujimaki; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

  9 in total
  8 in total

1.  Activity of newer fluoroquinolones in vitro against gram-positive bacteria.

Authors:  G M Eliopoulos
Journal:  Drugs       Date:  1999       Impact factor: 9.546

2.  Clinical study of T-3761 in obstetrics and gynaecology.

Authors:  S Matsuda
Journal:  Drugs       Date:  1995       Impact factor: 9.546

3.  Pharmacokinetic and clinical studies of T-3761 in otorhinolaryngeal infections.

Authors:  A Shinkawa; H Kimura; M Sakai; H Miyake
Journal:  Drugs       Date:  1995       Impact factor: 9.546

4.  Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent.

Authors:  D Gargallo-Viola; S Ferrer; E Tudela; M Robert; R Coll; R Roser; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 5.  In vitro activity of fluoroquinolones against gram-positive bacteria.

Authors:  G M Eliopoulos
Journal:  Drugs       Date:  1995       Impact factor: 9.546

6.  In vitro anti-Mycobacterium avium activities of quinolones: predicted active structures and mechanistic considerations.

Authors:  G Klopman; J Y Li; S Wang; A J Pearson; K Chang; M R Jacobs; S Bajaksouzian; J J Ellner
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

Review 7.  Update on clinical significance of coagulase-negative staphylococci.

Authors:  W E Kloos; T L Bannerman
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

8.  Concentration-Dependent Activity of Pazufloxacin against Pseudomonas aeruginosa: An In Vivo Pharmacokinetic/Pharmacodynamic Study.

Authors:  Yasuhiro Umezaki; Kazuaki Matsumoto; Kazuro Ikawa; Yuta Yokoyama; Yuki Enoki; Akari Shigemi; Erika Watanabe; Koyo Nakamura; Keiichiro Ueno; Hideyuki Terazono; Norifumi Morikawa; Yasuo Takeda
Journal:  Antibiotics (Basel)       Date:  2022-07-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.